Combining targeted agents with checkpoint inhibitors in cutaneous T-cell lymphoma
"Both targeted agents, such as brentuximab vedotin, and checkpoint inhibitors, such as pembrolizumab, have shown activity in a subset of patients with cutaneous T-cell lymphoma. Francine Foss, MD...
Author: VJHemOnc
Added: 11/16/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 16, 2017 Category: Cancer & Oncology Source Type: podcasts
Pain meds in the ED, TNF inhibitors and lymphoma, fall prevention, and more.
Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the November 07, 2017 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - November 7, 2017 Category: General Medicine Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts
Denosumab gives clinicians more choices for treating multiple myeloma
Raje, Noopur MD of the Massachusetts General Hospital Cancer Center highlights that denosumab now gives clinicians more choices for treating multiple myeloma.
Author: Lymphoma-Myeloma-Conference
Added: 11/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 7, 2017 Category: Cancer & Oncology Source Type: podcasts
What are the next steps for Denosumab?
Raje, Noopur MD of the Massachusetts General Hospital Cancer Center discusses the next steps for Denosumab at the Lymphoma-Myeloma 2017 meeting in New York.
Author: Lymphoma-Myeloma-Conference
Added: 11/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 7, 2017 Category: Cancer & Oncology Source Type: podcasts
Is it possible to switch from one bone targeting agent to another
Raje, Noopur S., MD from Massachusetts General Hospital Cancer Center asks the question is it possible to switch from one bone targeting agent to another in multiple myeloma?
Author: Lymphoma-Myeloma-Conference
Added: 11/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 7, 2017 Category: Cancer & Oncology Source Type: podcasts
Is it possible to switch from one bone targeting agent to another in Multiple Myeloma?
Raje, Noopur, MD of Massachusetts General Hospital Cancer Center discusses if it is possible to switch from one bone targeting agent to another in Multiple Myeloma?
Author: Lymphoma-Myeloma-Conference
Added: 11/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 7, 2017 Category: Cancer & Oncology Source Type: podcasts
Denosumab More Cost Effective v Zoledronic Acid in Multiple Myeloma
Noopur Raje, MD of Massachusetts General Hospital Cancer Center outlines how the recently released economic analysis of Denosumab v. Zoledronic Acid found that Denosumab was overall more cost effectiv...
Author: Lymphoma-Myeloma-Conference
Added: 11/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 7, 2017 Category: Cancer & Oncology Source Type: podcasts
Economic Analysis Denosumab v Zoledronic Acid in Multiple Myeloma
Noopur Raje, MD of Massachusetts General Hospital Cancer Center discusses her findings in which Denosumab is favored in newly diagnosed multiple myeloma patients from a recent economic analysis of Den...
Author: Lymphoma-Myeloma-Conference
Added: 11/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 6, 2017 Category: Cancer & Oncology Source Type: podcasts
Michelle A. Fanale, MD - Expert Thoughts on Managing CD30-Expressing Lymphoma: From Disease Recognition to Treatment Selection
Expert Thoughts on Managing CD30-Expressing Lymphoma: From Disease Recognition to Treatment Selection (Source: PeerView CME/CE Audio Podcast - Oncology)
Source: PeerView CME/CE Audio Podcast - Oncology - August 14, 2017 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
Remembering Suzanne: Celebrating the Life of a Cancer Patient
When a life is cut short, remembering your loved one can be difficult and yet rewarding. Suzanne Hyte was diagnosed with Hodgkin lymphoma at an early age and although she lived an optimistic, upbeat a...
Author: patientpower
Added: 07/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - July 19, 2017 Category: Cancer & Oncology Source Type: podcasts
Ahmet Dogan, MD, PhD - A Pathology Perspective on CD30 Expression in Lymphoma: Testing, Interpretation, and Strategies for Interprofessional Collaboration
A Pathology Perspective on CD30 Expression in Lymphoma: Testing, Interpretation, and Strategies for Interprofessional Collaboration (Source: PeerView CME/CE Audio Podcast - Oncology)
Source: PeerView CME/CE Audio Podcast - Oncology - July 17, 2017 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
Do CAR T-Cell therapies look promising for the treatment of NHL?
Jeff Sharman, MD of Willamette Valley Cancer Center discusses whether or not CAR T-cell therapy is promising for the treatment of non-hodgkin lymphoma. This was recorded at the 2017 ASCO Annual Meetin...
Author: obr
Added: 06/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2017 Category: Cancer & Oncology Source Type: podcasts
